Abstract | BACKGROUND: CASE DESCRIPTION: LITERATURE REVIEW: To our knowledge, there have been no reports of infection or malignancy with low-dose denosumab administration for osteoporosis. However, while there are relatively few reported side effects, the safety of denosumab and adverse events seen with higher doses, as used in treatment of giant cell tumors of bone are not well defined. CLINICAL RELEVANCE:
|
Authors | Luis A Aponte-Tinao, Nicolas S Piuzzi, Pablo Roitman, German L Farfalli |
Journal | Clinical orthopaedics and related research
(Clin Orthop Relat Res)
Vol. 473
Issue 9
Pg. 3050-5
(Sep 2015)
ISSN: 1528-1132 [Electronic] United States |
PMID | 25758379
(Publication Type: Case Reports, Journal Article, Review)
|
Chemical References |
- Antineoplastic Agents
- Denosumab
|
Topics |
- Amputation, Surgical
- Antineoplastic Agents
(adverse effects)
- Biopsy
- Bone Neoplasms
(drug therapy, pathology)
- Denosumab
(adverse effects)
- Female
- Giant Cell Tumor of Bone
(diagnostic imaging, drug therapy, pathology, surgery)
- Humans
- Magnetic Resonance Imaging
- Neoplasm Grading
- Neoplasm Recurrence, Local
- Radiography
- Risk Assessment
- Risk Factors
- Sarcoma
(chemically induced, pathology, surgery)
- Tibia
(drug effects, pathology)
- Time Factors
- Treatment Outcome
- Young Adult
|